Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients With Postbariatric Hypoglycemia
Conditions
Interventions
exendin 9-39
Placebo
Locations
5
United States
Stanford University
Palo Alto, California, United States
University of Colorado, Denver
Aurora, Colorado, United States
Johns Hopkins University
Baltimore, Maryland, United States
Duke Early Phase Clinical Research
Durham, North Carolina, United States
University of Wisconsin
Madison, Wisconsin, United States
Start Date
March 19, 2018
Primary Completion Date
January 30, 2019
Completion Date
March 15, 2019
Last Updated
July 18, 2022
Lead Sponsor
Eiger BioPharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions